Net sales of 97,406 million yen (up 10.3% YoY), operating loss of 2,927 million yen, net income attributable to owners of the parent of 13,779 million yen (up 15.2%), R&D expenses of 22,521 million yen (up 74.7%), and projected net sales of 95,700 million yen for FY2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4547-20260512-01.pdf","jir_short_summary":"Net sales of 97,406 million yen (up 10.3% YoY), operating loss of 2,927 million yen, net income attributable to owners of the parent of 13,779 million yen (up 15.2%), R&D expenses of 22,521 million yen (up 74.7%), and projected net sales of 95,700 million yen for FY2027.","jir_summary":"### Performance Overview\nNet sales for the fiscal year ending March 2026 reached 97,406 million yen, an increase of 10.3% compared to the same period last year, setting a record high. Pharmaceuticals business grew by 3.5%, while other business segments increased by 49.3%. Operating loss was 2,927 million yen; however, gains from sale of investment securities were recorded as extraordinary income, leading to net income of 13,779 million yen (up 15.2%). R&D expenses surged by 74.7% to 22,521 million yen, contributed by technology licensing agreements for thyroid eye disease treatments and the start of clinical trials for new products.\n\n### Segment Performance and Future Outlook\nPharmaceutical segment net sales amounted to 77,950 million yen (up 3.5%), driven by growth in domestic products such as Beova, Tabneos, Korsba, and Tabaris. Overseas license revenues increased through export sales, despite a decline in licensing fees due to a reactionary decrease. Other businesses saw significant increases due to higher orders related to GIGA School initiatives in the information services sector. For FY2027, net sales are projected to be 95,700 million yen (down 1.8%), with operating income of 4,400 million yen and net income of 14,500 million yen. R&D expenses are expected to decrease to 16,500 million yen, but the company will continue advancing clinical development themes.","jir_financial_highlights":"Net Sales: 97,406 million yen (up 10.3% YoY)\nOperating Income: \u25b32,927 million yen (Unknown (\u25b33.0% YoY))\nOrdinary Income: \u25b31,162 million yen (Unknown (\u25b31.2% YoY))\nNet Income Attributable to Owners of the Parent: 13,779 million yen (up 15.2% YoY)\nResearch and Development Expenses: 22,521 million yen (up 74.7% YoY)\nPharmaceutical Business Net Sales: 77,950 million yen (up 3.5% YoY)\nOther Business Net Sales: 19,455 million yen (up 49.3% YoY)","jir_category":"","jir_hashtags":"#KisseiPharmaceutical, #FinancialResultsBriefing, #JapaneseStocks","jir_key_figures":"Net Sales: 97,406 million yen (up 10.3% YoY)\nOperating Income: \u25b32,927 million yen (loss)\nNet Income Attributable to Owners of the Parent: 13,779 million yen (up 15.2% YoY)","jir_meta_title":"\u3010Kissei Pharmaceutical\u3011 FY2026 Financial Results \u2014 Net Sales 97,406 million yen (up 10.3% YoY)","jir_meta_description":"Kissei Pharmaceutical's FY2026 financial results briefing. Net sales reached 97,406 million yen (up 10.3% YoY), and net income was 13,779 million yen (up 15.2%), the highest ever. R&D expenses also increased by 74.7%.","jir_og_title":"\u3010Kissei Pharmaceutical\u3011 FY2026 Financial Results \u2014 Net Sales 97,406 million yen (up 10.3%)","jir_og_description":"Kissei Pharmaceutical FY2026 financial results. Net sales of 97,406 million yen and net income of 13,779 million yen increased profits. R&D expenses also rose significantly.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48041","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n